Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bioniche Life Sciences (Bioniche), a research-based, technology driven Canadian biopharmaceutical company, has received a $4m milestone payment from its development partner, Endo Pharmaceuticals.
Subscribe to our email newsletter
Bioniche said that the current milestone payment was triggered by Urocidin attaining a contractual efficacy goal from an ongoing US Food and Drug Administration (FDA) Phase III registration trial.
Urocidin is a product for non-muscle-invasive bladder cancer that is refractory to current first-line therapy.
This clinical trial, which was started in late 2006, involves the use of an intravesical formulation of a patented mycobacterial cell wall composition, Mycobacterial Cell Wall-DNA Complex (MCC), known as Urocidin (or as EN3348) for treatment-refractory non-muscle-invasive bladder cancer.
As per the licensing agreement, Bioniche received an up-front payment of $20m in July, 2009, and has the potential to receive a total of $110m in payments associated with the achievement of certain clinical, regulatory and commercial milestones.
Bioniche said that it has received four development milestones since November, 2009, resulting in total payments of $18m and that future milestones will be announced as they are achieved.